Cargando…

Revisiting Secondary Information Related to Pharmacogenetic Testing

Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guide...

Descripción completa

Detalles Bibliográficos
Autor principal: Haga, Susanne B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517135/
https://www.ncbi.nlm.nih.gov/pubmed/34659361
http://dx.doi.org/10.3389/fgene.2021.741395
_version_ 1784583947003363328
author Haga, Susanne B.
author_facet Haga, Susanne B.
author_sort Haga, Susanne B.
collection PubMed
description Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings.
format Online
Article
Text
id pubmed-8517135
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85171352021-10-16 Revisiting Secondary Information Related to Pharmacogenetic Testing Haga, Susanne B. Front Genet Genetics Incidental or secondary findings have been a major part of the discussion of genomic medicine research and clinical applications. For pharmacogenetic (PGx) testing, secondary findings arise due to the pleiotropic effects of pharmacogenes, often related to their endogenous functions. Unlike the guidelines that have been developed for whole exome or genome sequencing applications for management of secondary findings (though slightly different from PGx testing in that these refer to detection of variants in multiple genes, some with clinical significance and actionability), no corresponding guidelines have been developed for PGx clinical laboratories. Nonetheless, patient and provider education will remain key components of any PGx testing program to minimize adverse responses related to secondary findings. Frontiers Media S.A. 2021-10-01 /pmc/articles/PMC8517135/ /pubmed/34659361 http://dx.doi.org/10.3389/fgene.2021.741395 Text en Copyright © 2021 Haga. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Haga, Susanne B.
Revisiting Secondary Information Related to Pharmacogenetic Testing
title Revisiting Secondary Information Related to Pharmacogenetic Testing
title_full Revisiting Secondary Information Related to Pharmacogenetic Testing
title_fullStr Revisiting Secondary Information Related to Pharmacogenetic Testing
title_full_unstemmed Revisiting Secondary Information Related to Pharmacogenetic Testing
title_short Revisiting Secondary Information Related to Pharmacogenetic Testing
title_sort revisiting secondary information related to pharmacogenetic testing
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517135/
https://www.ncbi.nlm.nih.gov/pubmed/34659361
http://dx.doi.org/10.3389/fgene.2021.741395
work_keys_str_mv AT hagasusanneb revisitingsecondaryinformationrelatedtopharmacogenetictesting